Voyager Therapeutics Inc (VYGR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Voyager Therapeutics Inc (VYGR) has a cash flow conversion efficiency ratio of -0.141x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.05 Million) by net assets ($219.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VYGR net asset quality index to measure how much of total assets are equity-financed.
Voyager Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Voyager Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VYGR cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Voyager Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Voyager Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Macpower CNC Machines Limited
NSE:MACPOWER
|
0.005x |
|
Wemade Co.Ltd
KQ:112040
|
0.007x |
|
NervGen Pharma Corp.
NASDAQ:NGEN
|
-1.505x |
|
Hostelworld Group PLC
IR:HSW
|
0.076x |
|
Pruksa Holding Public Company Limited
F:2PR3
|
0.067x |
|
Kginicis Co.Ltd
KQ:035600
|
0.020x |
|
Yatra Online Limited
NSE:YATRA
|
0.110x |
|
Garuda Construction & Engineering
NSE:GARUDA
|
0.011x |
Annual Cash Flow Conversion Efficiency for Voyager Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Voyager Therapeutics Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Voyager Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $299.76 Million | $-15.31 Million | -0.051x | -115.49% |
| 2023-12-31 | $236.32 Million | $77.92 Million | 0.330x | +255.57% |
| 2022-12-31 | $59.02 Million | $-12.51 Million | -0.212x | +62.36% |
| 2021-12-31 | $95.06 Million | $-53.52 Million | -0.563x | +10.15% |
| 2020-12-31 | $154.32 Million | $-96.72 Million | -0.627x | -228.15% |
| 2019-12-31 | $99.51 Million | $48.67 Million | 0.489x | +242.97% |
| 2018-12-31 | $46.45 Million | $-15.89 Million | -0.342x | +25.26% |
| 2017-12-31 | $134.05 Million | $-61.35 Million | -0.458x | -46.43% |
| 2016-12-31 | $135.92 Million | $-42.48 Million | -0.313x | -227.95% |
| 2015-12-31 | $169.07 Million | $41.30 Million | 0.244x | +102.35% |
| 2014-12-31 | $1.15 Million | $-11.92 Million | -10.372x | -829.50% |
| 2013-12-31 | $-3.83 Million | $-5.45 Million | 1.422x | -- |
About Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene the… Read more